IRLAB A — IRLAB Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK165.12m
- SEK155.10m
- SEK57.46m
Brief: IRLAB Q3 Operational Profit Swings To Loss Of Sek 23.9 Mln
Brief: Irlab Q2 Operating Loss At SEK 27.1 Million
Brief: IRLAB Expands Phase IIb/III Study
Brief: IRLAB Therapeutics Appoints Richard Godfrey As New CEO
Brief: IRLAB Q1 Operating Loss Widens To SEK 29.0 Mln
Brief: Irlab Acquires Know-How For SEK 0.5 Million
Brief: IRLAB Nominates New Candidate Drug, IRL757
Brief: Irlab Q4 Operating Loss Widens to SEK 22.6 Mln
Brief: Irlab Therapeutics Q3 Oper Loss Sek 121.7 mln
Brief: Irlab Therapeutics Obtains Patent For Candidate Pirepemat
Brief: Irlab Therapeutics Q2 Operating Loss Widens To SEK 26.5 Million
Brief: Ipsen, Irlab Enter Exclusive Worldwide Licensing Agreement To Improve Lives Of People Living With Parkinson’s Disease
Brief: Ipsen Obtains Exclusive Worldwide Rights To Develop And Commercialise Mesdopetam
Brief: Irlab’S Drug Candidate Pirepemat’S Phase I Data Published In Scientific Journal Cpdd
Brief: Irlab Therapeutics Q1 Operating Loss Widens To SEK 20.0 Mln
Brief: Irlab's Drug Candidate Mesdopetam's Mechanism Of Action Receives Confirmation By Independent Scientists
Brief: Irlab Q4 Operating Loss Narrows To SEK 19.4 Million
Brief: IRLAB Presents Application Of Deep Learning On Multidimensional CNS Drug Efficacy Data
Brief: IRLAB Says Mesdopetam Could Prevent Dyskinesia In Parkinson's